Last updated: 11/07/2018 19:20:15
A Multi-Centre, Double-Blind, Parallel Group Study to Evaluate the Efficacy of SEREVENT 50mg BID Versus Placebo BID all Administered via the Multi Dose Powder Inhaler (DISKUS/ACCUHALER) in Terms of Symptoms in the Treatment of Patients With Chronic Obstructive Pulmonary Disease
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Multi-Centre, Double-Blind, Parallel Group Study to Evaluate the Efficacy of SEREVENT 50mg BID Versus Placebo BID all Administered via the Multi Dose Powder Inhaler (DISKUS/ACCUHALER) in Terms of Symptoms in the Treatment of Patients With Chronic Obstructive Pulmonary Disease
Trial description: A Multi-Centre, Double-Blind, Parallel Group Study to Evaluate the Efficacy of SEREVENT 50mg BID Versus Placebo BID all Administered via the Multi Dose Powder Inhaler (DISKUS/ACCUHALER) in Terms of Symptoms in the Treatment of Patients With Chronic Obstructive Pulmonary Disease
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Abstract: Chapman, K MD; Kuipers, A F MD; Goldstein, R MD, and James, M H MD, 63354. Addition of Salmeterol 50 MCG Bid to Anticholinergic Treatment in COPD [4/23/1999]. 4/28/1999: Chapman, K MD; Kuipers, A F MD; Goldstein, R MD, and James, M H MD, 3/9/2003. American Lung Association/American Thoracic Society 1999 International Conference; San Diego, CA; USA. 1999 Apr 23; c1999.
Chapman K, James MH, Kuipers AF, Goldstein R. Addition of salmeterol 50mcg bid to anticholinergic treatment in COPD. Am Rev Resp Crit Care Med 1999; 159 (3): A523.
Chapman, K. R.; Arvidsson, P.; Chuchalin, A. G.; Dhillon, D. P.; Faurschou, P.; Goldstein, R. S., and Kuipers, A. F. (Toronto Western Hospital, Ontario. [email protected]). The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease. [eng]. Chapman, Kenneth R; Arvidsson, Peter; Chuchalin, A G; Dhillon, D P; Faurschou, Peter; Goldstein, Roger S, and Kuipers, A F. Can Respir J. 2002 May-2002 Jun 30; 9(3):178-85; ISSN: Clinical Trial. Journal Article. Randomized Controlled Trial. 0 (Adrenergic beta-Agonists). 0 (Bronchodilator Agents). 0 (Cholinergic Antagonists). 0 (Placebos). 18559-94-9 (Albuterol). 89365-50-4 (salmeterol). Adrenergic beta-Agonists/*administration & dosage. Adult. Aged. Albuterol/*administration & dosage/*analogs & derivatives. Bronchodilator Agents/*administration & dosage. Cholinergic Antagonists/*administration & dosage. Double-Blind
Medical condition
Pulmonary Disease, Chronic Obstructive
Product
salmeterol
Collaborators
Not applicable
Study date(s)
N/A to Invalid Date
Type
Not applicable
Phase
4
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
Not applicable
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website